The European Commission has approved ICOTYDE® for eligible psoriasis patients aged 12 and over. The once-daily oral peptide ...
Johnson & Johnson's ICOTYDE oral psoriasis pill maintains 70% clear/almost-clear skin rates at 2 years, with no new safety ...
(AMGN) has completed a Phase 3 study called “A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast (AMG 407) in Japanese Pediatric Subjects From 6 ...
Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the ...
Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter ...
Yusimry is indicated to treat a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn’s ...
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis ...
An investigational therapy, SSGJ-608, was associated with substantial skin clearance through 52 weeks among patients with plaque psoriasis.
Ascletis Pharma Inc. Announces Positive Results From 28-Day Proof-Of-Concept Clinical Study In U.S. For ASC50 For The Treatment Of Plaque Psoriasis CI Sep. 08 Ascletis Pharma Initiates Phase I Study ...
The once-daily IL-23-targeted pill showed high rates of skin clearance and itch improvement in adults with moderate-to-severe plaque psoriasis.
An international research team has discovered a previously unknown mechanism that plays a key role in the signaling pathways ...
Plaque psoriasis affects ~2% of the population and is linked to cardiovascular disease (CVD), psoriatic arthritis (PsA), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results